Venous thromboembolism and pregnancy by D’Uva, Maristella et al.
© 2010 D’Uva et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Blood Medicine 2010:1 9–12
Journal of Blood Medicine
R E V I E W
open access to scientific and medical research
Open Access Full Text Article

Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Venous thromboembolism and pregnancy
Maristella D’Uva1 
Pierpaolo Di Micco2 
Ida Strina1 
Giuseppe De Placido
1Department of Obstetrics 
and Gynecology and Human 
Reproduction, “Federico II” University 
of Naples, Naples, Italy; 2Internal 
Medicine Division, Buonconsiglio 
Fatebenefratelli Hospital of Naples, 
Naples, Italy
Correspondence: Pierpaolo Di Micco
Internal Medicine Division, Buonconsiglio 
Fatebenefratelli, Hospital of Naples, 
Via San Giacomo dei Capri 69, I-80131, 
Naples, Italy
Tel +39 33 9807 8146
Email pdimicco@libero.it
Abstract: In recent decades, the association between a hypercoagulable state and its causes 
and adverse pregnancy outcome, in particular recurrent pregnancy loss (RPL) has been studied 
  extensively. Although the first studies were focused only on the association between thrombophilia 
and RPL, subsequent studies underlined also a potential role of antithrombotic treatment to 
prevent vascular complication such as venous thromboembolism (VTE) during pregnancy. 
Thromboprophylaxis should be considered also for pregnant subjects carriers of molecular 
thrombophilia or that previously experienced VTE, in order to prevent VTE during pregnancy, 
while antithrombotic treatment for VTE should be performed during all pregnant periods.
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Hypercoagulable state during pregnancy
Recurrent pregnancy loss (RPL) represents a major health problem with two to three or 
more losses in up to 5% of women of reproductive age and is actually one of the most 
common causes of female sterility.1 Several reports identify inherited predisposition 
to thrombophilia as one of the main causes of RPL in particular if several diseases 
potentially responsible for RPL have been already excluded such as endocrine diseases 
(eg, ovarian dysfunction, anovulation, hypopituitarism, diabetes), uterine malformation, 
genetic alterations (eg, chromosomal aberrations), inflammatory diseases (in particular 
systemic lupus erythematosus), and infectious diseases.2–5
From a pathological point of view, women affected by thrombophilia show during 
their pregnancy a hypercoagulable state, that is already increased during pregnancy. 
This combined increase in thrombophilic state may impair placental flow, its function 
and fetal growth and may predispose to develop venous thrombosis.6
During pregnancy we may observe many changes in the haemostatic balance 
with a trend toward thrombophilia in order to be prompt for the hemostatic chal-
lenge of delivery.2,6,7 Thus, pregnancy is a condition associated to thrombophilia 
per se and for this reason it is associated with the increase of several clotting factors 
(ie, factor VIII, von Willebrand factor, fibrinogen, factor VII).7 Moreover, also other 
markers of a hypercoagulable state are increased during pregnancy, such as D-dimer 
and/or prothrombin fragment 1 + 2.7,8 For this reason we may observe episodes of 
venous thromboembolism (VTE) during pregnancy.9 So, women carrying further 
thrombotic risk factors (eg, inherited thrombophilia) show an additional increase in 
risk of thrombotic events during pregnancy such as venous thromboembolism and/or 
abortion.10Journal of Blood Medicine 2010:1 10
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Episodes of acute VTE during pregnancy should be 
treated as in nonpregnant women (ie, with full doses of 
unfractionated heparin (UFH) monitored with activated 
partial thromboplastin time, or with low-molecular-weight 
heparin (LMWH), twice daily with possible monitoring 
according to Xa levels.14–18 However, many variables should 
be considered during heparin treatment in pregnancy because 
the several metabolic changes during pregnancy may also 
modify the plasma concentration and bioavailability of any 
type of heparin.17
Recently other data from RIETE registry confirmed that 
pregnant women with VTE show few clinical symptoms and 
frequently do not have comorbidities.19 The main frequent 
symptoms of VTE during pregnancy are painful limb and 
lower limb edema associated to chest pain or dyspnea,19 and 
relevant changes in electrocardiography may be found in 
pregnant women with VTE in particular, such as the presence 
of negative waves.19
Treatment in this report was based mainly on LMWH 
(nearly 80%) with high daily doses (185 U\Kg daily), while 
UFH was used in nearly 10% of patients as acute treatment. 
Vena cava filter was considered only for 4% of patients 
and thromblysis for 1% of patients. Antivitamin K drugs 
were administered for long-term treatment in nearly 20% 
of patients.
Anticoagulant treatment after acute VTE in pregnancy 
should be continued, in particular if needed for clinical 
conditions, but it should be stopped when the patient is near 
to delivery.2 Anticoagulant treatment should be re-started 
after delivery in order to avoid recurrences, based mainly on 
oral anticoagulation according to the required International 
Normalized Ratio range.2
Thrombophilia and VTE 
thromboprophylaxis during 
pregnancy
Thromboprophylaxis may be divided into primary 
  prophylaxis for patients that never experienced VTE or 
secondary prophylaxis in subjects who previously suffered 
from VTE.
For pregnant women primary thromboprophylaxis is 
recommended in case of Cesarean section and during the 
puerperium in most cases.20
Moreover, primary thromboprophylaxis is suggested 
for asymptomatic pregnant women if one of these 
  conditions is present: antithrombin deficiency; more than 
VTE and pulmonary embolism (PE), in fact, continue 
to be a leading cause of maternal death during pregnancy or 
postpartum and may cause significant morbidity of pregnant 
women. Although DVT and PE occur infrequently during 
pregnancy, they represent one of the most serious complication 
and important issues concerning their natural history, preven-
tion and therapy remain unresolved during pregnancy.
This review was focused on the management of venous 
thromboembolism occurrence and its prophylaxis during 
pregnancy.
Occurrence of   VTE during 
pregnancy and its causes
VTE is a multifactorial disease which involves acquired 
and inherited risk factors.11,12 Molecular thrombophilia, 
in particular inherited thrombophilia, is involved in the 
pathophysiology of juvenile VTE, whereas pregnancy is 
recognized as one of the acquired thrombotic risk factors for 
VTE.11 However, not all pregnant women develop VTE dur-
ing pregnancy, therefore a clear evaluation of the VTE risk is 
suggested in any case. Data on all types of patients that should 
have thromboprophylaxis performed during pregnancy are 
really controversial in the literature. There is only one way 
to perform thromboprophylaxis during pregnancy, that is, 
in women that are at high risk of VTE because they are car-
riers of relevant predisposing factors for VTE. In this field, 
antithrombin deficiency seems to be the inherited disorder 
that patients more at risk of VTE during pregnancy show, 
but other molecular conditions associated with inherited 
thrombophilia have also been frequently identified.
However, most previous studies evaluating pregnancy-
associated thromboembolic events have used clinical criteria 
only for diagnosis or included few patients.
Recently, the Registry of Patients with Venous Throm-
boembolism (RIETE) underlined several interesting aspects 
of VTE during pregnancy. VTE is more common in the first 
trimester of pregnancy compared to the second and third 
trimesters; 13 moreover, this registry underlined the need for 
starting thromboprophylaxis during pregnancy as soon as 
possible in pregnant women at risk for thrombotic events.13 
Furthermore, nearly 55% of pregnant patients with VTE dur-
ing pregnancy were carriers of molecular thrombophilia.13 
In this field, factor V Leiden and prothrombin A20210G are 
the more common gene variants present in this population.13 
Once therapy was started, VTE recurrences seem to be 
rare while bleeding complications are more frequent after 
delivery.13Journal of Blood Medicine 2010:1 11
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one thrombophilic condition (eg, homozygosity for one 
thrombophilic gene polymorphism or two or more hetero-
zygosities for thrombophilic defects, or the presence of one 
or more inherited thrombophilic defects associated to one or 
more acquired thrombophilic defects); and first-degree rela-
tive with a history of severe juvenile VTE.21 Furthermore, 
primary thromboprophylaxis has been recently suggested 
for pregnant carriers of thrombophilic conditions without 
previous history of VTE.13
In pregnant women with previous VTE, secondary throm-
boprophylaxis during pregnancy should be performed.22,23 
According to the data available from the literature we may 
perform an active pharmacological thromboprophylaxis 
based on the administration of UFH or LMWH.22,23
Furthermore, pharmacological thromboprophylaxis 
is suggested if further thrombotic risk factors are present 
during pregnancy (ie, prolonged bed rest, recent surgery, 
obesity, autoimmune disease with or without antiphos-
pholipid syndrome, infections, nephrotic syndrome, pre-
eclampsia).
However, pharmacological thromboprophylaxis should 
be considered during the puerperium for about six to eight 
weeks and based on the administration of UFH or LMWH 
once daily if several thrombotic risk factors are presence 
because the frequent appearance of VTE during first weeks 
of puerperium.20
Conclusion
VTE is multifactorial disease that recognizes several risk 
factors in which pregnancy is included. Although, not all 
pregnant women develop VTE during pregnancy, VTE is 
still a cause of maternal death during pregnancy or post-
partum and cause also a significant subsequent morbidity. 
However, in these years most of the protocols for treatment 
of DVT or PE during pregnancy or postpartum were based on 
data extrapolated from the nonpregnant population, mainly 
because these patients have been systematically excluded 
from participating in clinical trial, so emerging data about 
treatment and\or prophylaxis for VTE during pregnancy were 
not universally accepted. In this short review we reported 
recent data that confirmed a relevant role of molecular throm-
bophilia in the occurrence of VTE during pregnancy and 
the efficacy and safety of anticoagulant therapy in pregnant 
women with VTE. Considering VTE prophylaxis as a clear 
evaluation of thrombotic risk is suggested because VTE 
prophylaxis actually is considered only for high-risk patients 
and further data should be provided by further studies.
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